Antila Lifesciences Private Limited

Antila Lifesciences Private Limited, established on December 21, 2010, is a privately held pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories. As of March 2026, Antila Lifesciences has an authorized capital of ₹5 million and a paid-up capital of ₹1.67 million. The Corporate Identification Number (CIN) is U24230GJ2010PTC063306, and the company is registered under the Registrar of Companies, Ahmedabad.

The company's registered office is located at 814, Devpath B/H Lal Bunglow Off C.G. Road, Navrangpura, Ahmedabad, Gujarat, 380006. Antila Lifesciences operates as a non-government company limited by shares and is unlisted. The latest Annual General Meeting (AGM) was held on September 30, 2025, with the balance sheet filed on March 31, 2025.

Antila Lifesciences operates a WHO-GMP certified state-of-the-art manufacturing facility in Ahmedabad, Gujarat. The facility is equipped to produce a wide range of pharmaceutical formulations, including tablets, capsules, syrups, and injections, adhering to international quality standards. The company's manufacturing operations are integrated with its marketing and distribution channels, enabling efficient production and export processes.

The leadership team at Antila Lifesciences comprises three directors:

• Rutwa Vijaykumar Shah: Director since December 21, 2010.
• Parth Mayurbhai Shah: Director since December 21, 2010.
• Sanjay Jashwantlal Shah: Director since December 21, 2010.

These directors have been instrumental in steering the company's growth and expansion in the pharmaceutical export sector.

Antila Lifesciences has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and certifications to export its pharmaceutical formulations to these regions. Specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed. However, the company's adherence to WHO-GMP standards and its commitment to quality manufacturing practices support its ability to meet the stringent requirements of these markets.

Antila Lifesciences has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's compliance with WHO-GMP standards facilitates its entry into these regions, enabling access to a broader customer base. While specific market penetration details are not publicly available, the company's global reach and diverse product portfolio position it well to capitalize on opportunities in these emerging markets.

Antila Lifesciences demonstrates a diversified geographic strategy by exporting its pharmaceutical formulations to over 40 countries. This broad market presence mitigates concentration risk and allows the company to leverage growth opportunities across different regions. The strategic direction focuses on expanding its footprint in both regulated and emerging markets, supported by its WHO-GMP certified manufacturing facility and commitment to quality.

Specific details regarding Antila Lifesciences' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the company's adherence to WHO-GMP standards and its state-of-the-art manufacturing facility suggest a commitment to meeting international regulatory requirements, including those of the FDA.

Antila Lifesciences' manufacturing facility is WHO-GMP certified, indicating compliance with the World Health Organization's Good Manufacturing Practices. This certification underscores the company's commitment to producing high-quality pharmaceutical formulations. Specific details regarding EU GMP certificates and EDQM status are not publicly available.

Antila Lifesciences holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards for pharmaceutical manufacturing. The company has also obtained necessary approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its export operations. Specific details regarding these approvals are not publicly disclosed.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Antila Lifesciences. The company's adherence to WHO-GMP standards and its commitment to quality manufacturing practices suggest a proactive approach to regulatory compliance.

Antila Lifesciences operates in a competitive pharmaceutical export market, facing competition from both domestic and international companies. While specific market share comparisons and head-to-head analyses are not publicly available, the company's WHO-GMP certified manufacturing facility and diverse product portfolio position it as a competent player in the industry. The company's focus on quality and customer satisfaction enhances its competitive edge.

Antila Lifesciences' key differentiators include its WHO-GMP certified manufacturing facility, a broad range of pharmaceutical formulations, and a commitment to quality and customer satisfaction. The company's adherence to international quality standards and its focus on continuous improvement and innovation contribute to its competitive advantages.

Antila Lifesciences' current strategic direction focuses on expanding its presence in both regulated and emerging markets by leveraging its WHO-GMP certified manufacturing facility and diverse product portfolio. The company's future outlook includes exploring new growth opportunities through innovative formulations and maintaining a strong commitment to quality and customer satisfaction.

Antila Lifesciences has demonstrated a consistent track record in pharmaceutical manufacturing, with a focus on quality and customer satisfaction. The company's export volume and consistency are supported by its WHO-GMP certified manufacturing facility and adherence to international quality standards. Reliability indicators include a dedicated and trained workforce, a state-of-the-art manufacturing facility, and a commitment to continuous improvement and innovation.

Importers should verify the following certifications when considering Antila Lifesciences as a supplier:

• FDA Facility Registration: To confirm the company's registration with the U.S. Food and Drug Administration.
• WHO-GMP Certification: To ensure compliance with the World Health Organization's Good Manufacturing Practices.
• EU GMP Certificate: To verify adherence to European Union Good Manufacturing Practices.
• ISO Certification: To confirm compliance with international quality management standards.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting Antila Lifesciences directly.

When conducting due diligence on Antila Lifesciences, consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications.
• Assess Financial Health: Review the company's financial statements for profitability and growth trends.
• Evaluate Manufacturing Capabilities: Inspect the manufacturing facility for compliance with international standards.
• Check Export Records: Assess the company's export history and consistency in delivery.
• Review Customer Feedback: Seek testimonials or reviews from existing clients regarding product quality and service.

Red flags to watch for include expired or invalid certifications, inconsistent financial performance, and negative customer feedback. Recommended pre-order checks involve requesting copies of certifications, financial statements, and recent inspection reports.